12.01.09
A recent human clinical trial supports the beneficial effects of PeptiBal, from innoVactiv, on immune health. In this randomized, double-blinded, placebo-controlled human clinical trial led by the Institute of Nutraceuticals and Functional Foods of Laval University, Quebec City, Canada, 50 healthy volunteers were assigned to the treatment (daily dose of 300 mg of PeptiBal) or placebo groups.
The study showed that PeptiBal produced a statistically significant increase in IgA production in men by 17.4% over placebo after 28 days (P vs. baseline = 0.02). Additionally, PeptiBal produced a 14.7% increase in IgA levels vs. placebo in as little as 14 days. Produced when the body is in an overall anti-inflammatory state, IgA is an important determinant of passive immunity, indicating an improvement in active immuno-surveillance state. For further information: www.innovactiv.com
The study showed that PeptiBal produced a statistically significant increase in IgA production in men by 17.4% over placebo after 28 days (P vs. baseline = 0.02). Additionally, PeptiBal produced a 14.7% increase in IgA levels vs. placebo in as little as 14 days. Produced when the body is in an overall anti-inflammatory state, IgA is an important determinant of passive immunity, indicating an improvement in active immuno-surveillance state. For further information: www.innovactiv.com
